Ovarian Cancer Diagnostics Market
Ovarian Cancer Diagnostics Market By Cancer Type (Epithelial Tumor Diagnostics, Germ Cell Carcinoma Tumor Diagnostics, Stromal Carcinoma Tumor Diagnostics), By Test Type, By End User - Forecast to 2021–2031
Analysis of Ovarian Cancer Diagnostics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ovarian Cancer Diagnostics Market Outlook
This global ovarian cancer diagnostics market analysis by Fact.MR predicts the industry to expand at a robust CAGR of 7% from 2021 to 2031.
| Report Attributes | Details |
|---|---|
| Market CAGR (2021 to 2031) | 7% |
| North America Market Share | 45% |
| Market Value in 2020 | US$ 1.3 Bn |
| Fastest-Growing Markets in APAC Region | China and India |
Fact.MR, a market research and competitive intelligence provider, has performed detailed analysis of the industry and researched all the factors that affect market growth. As per the study, the ovarian cancer diagnostics market amassed revenue worth US$ 1.3 Bn in 2020.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Ovarian Cancer Diagnostics (2016 to 2020) Vs Market Forecasts (2021 to 2031)
Rising geriatric population all over the globe has completely transformed the healthcare industry across the globe. Aging women face the issue of ovarian cancer and as the number of aging women rises the instances of ovarian cancer are becoming more frequent.
Demand for ovarian cancer diagnostics is anticipated to be more as ovarian cancer becomes more common in the wake of rising aging women population. The need for accurate and in time diagnostic for ovarian cancer is increasing. Government backed initiatives and research is focusing on developing diagnostic methods that could detect the cancer in its early stages as the present diagnostic methods detect it when it has already spread at an advanced stage.
Increasing awareness, rising focus of government and other medical organizations to provide easy and in-time diagnosis of ovarian cancer are prime factors propelling the industry growth. The ovarian cancer diagnostics market growth to 2031 is estimated to rise at a CAGR of 7%.
What are the Different Types of Ovarian Cancer Diagnostic Imaging Techniques?
Imaging diagnostics play a vital role in ovarian cancer diagnosis and treatment as they allow professionals to explore the extent to which the tumors have spread. Some of the techniques are:
- Ultrasound for Ovarian Cancer Diagnostics
- PET Scan for Ovarian Cancer Diagnostics
- CT Scan for Ovarian Cancer Diagnostics
Demand for CT scan in ovarian cancer diagnostics is expected to increase over the next ten years due to its ability to provide insights on spread of tumor. The demand for PET scan in ovarian cancer diagnostics is expected to be moderate as it is not as commonly used.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What Does the Survey Say About Different Cancer Tests?
Due to the prevalence of different types of cancers and different nature of tumors there are a wide array of tests that can be employed to detect cancer.
Demand for CA 125 test in ovarian cancer diagnostics and HER 2 test is expected to be prominent over the forecast period in comparison to other tests. The sales of HER 2 test for ovarian cancer diagnostics are expected to see a modest growth as other tests gain popularity.
Epithelial tumors are most prominent in ovarian cancer and account for majority of instances hence demand for epithelial tumor diagnostics is substantially higher than the demand for germ cell carcinoma tumor diagnostics and stromal carcinoma tumor diagnostics demand combined.
Which Establishments are Essential for Ovarian Cancer Diagnostics?
Various healthcare establishments utilize ovarian cancer diagnostics for treatments to research. The most prominent are testing laboratories associated with hospitals and research centers.
Demand for ovarian cancer diagnostics in hospital associated labs is expected to be most prominent and predicted to increase as the instances of ovarian cancer rise. The demand for ovarian cancer diagnostics in independent diagnostic laboratories is anticipated to see a major rise as the affordability of equipment and instruments is realized. Independent diagnostic laboratories are increasing in number especially in emerging economies where the healthcare infrastructure is improving.
Demand for ovarian cancer diagnostics in cancer research institutes is expected to see a steady increase as demand for research increases. The demand for ovarian cancer diagnosis instruments is also expected to see a rise as research and developments in the industry progress.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Which Regions are Lucrative Markets for Ovarian Cancer Diagnostics?
This research details the global ovarian cancer diagnostics industry landscape in regions like North America, Latin America, Europe, APAC, and MEA.
North American region is estimated to hold a dominant stake in the global ovarian cancer diagnostics market share. The demand for BRCA test in ovarian cancer diagnostics is anticipated to rise at a positive CAGR of nearly 8% in the region. Europe is expected to account for a modest amount of market share in the global ovarian cancer diagnostics industry.
Demand for ovarian cancer diagnostics in APAC region is predicted to evolve at the fastest CAGR. The growth will majorly be driven by nations like India and China. The lack of awareness about the symptoms and treatments is a major factor that restricts the growth in APAC region.
The MEA region is expected to see relatively slower adoption of ovarian cancer diagnostics owing to the slow adoption of new diagnostic methods and limited healthcare spending potential.
Country-wise Analysis
How is the U.S. Ovarian Cancer Diagnostics Market Expected to Perform over the Decade?
The U.S. is anticipated to hold a dominant market share in the North American region. The demand for ovarian cancer diagnostics in the U.S. is majorly fueled by the increasing geriatric population, rising awareness, and the presence of prominent players. Technological advancements and increasing investments in research initiatives backed by the government also play a vital role in the development of the ovarian cancer diagnostics industry in the U.S.
What are the Trends of Ovarian Cancer Diagnostics in China?
China is expected to see some major changes in ovarian cancer diagnostics industry as it is expected to be one of the countries in APAC region with the fastest CAGR. While the nation has seen some decrease in cases over the past decade, the number of cases is anticipated to rise as the geriatric population increases over time. Government is placing control policies to curb the deaths and also backing research to promote ovarian cancer diagnostics.
Category-wise Analysis
How are Sales of KRAS Mutation Tests in Ovarian Cancer Diagnostics Shaping Up?
Research in developing new diagnostic tests and methods has increased substantially and researchers are coming up with new and advanced tests to diagnose tumors. Increased emphasis on genetic counseling is one of the major factors that is favoring the penetration of tests like KRAS mutation, HER 2, BRCA, etc. As research advances the penetration of these tests is expected to increase and the sales are anticipated to grow at a steady rate.
Competitive Landscape
Latest innovations in ovarian cancer diagnostics are much needed in the industry to spot cancer in its initial stages and treat it at that stage without causing much damage to the internal organs of the affected person. Top manufacturers of ovarian cancer diagnosis instruments are investing in research and development of devices and instruments that would aid in the diagnosis and treatment more effectively and efficiently.
- In August 2020, Chinese researchers from Suzhou Institute of Biomedical Engineering and Technology pioneered a non-invasive method that would aid in identifying and differentiating the types of ovarian cancer. It can differentiate between type I and type II ovarian cancer with an accuracy of 83%.
- MiRxes on the basis of a recent funding round has announced that it would be developing new assays for breast cancer, ovarian cancer, liver cancer and other cancers that would utilise the disease biomarkers revealed in the process of discovery. This part of company’s expansion of product portfolio with additional PCR tests.
- GinaLife an Israeli femtech start-up who is utilising AI and data science to identify women health issues at an early stage is pioneering an ovarian cancer test that would help with early detection of the condition. The test would enable women to examine themselves as it would be made easily accessible and available to women across the world. As of now it is just being tested in-clinic.
Ovarian Cancer Diagnostics Industry Report Scope
| Attributes | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | Units for Volume and US$ Millionn for Value |
| Key Regions Covered | North America; Latin America; Europe; APEJ; MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, U.K., France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Cancer Type, Test Type, End User, Region |
| Key Companies Profiled | Abbott Laboratories; Roche Holding A.G.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Luminex Corporation; Myriad Genetics Inc. |
| Pricing | Available upon Request |
Key Segments of Ovarian Cancer Diagnostics Industry Survey
-
By Cancer Type:
- Epithelial Tumor Diagnostics
- Germ Cell Carcinoma Tumor Diagnostics
- Stromal Carcinoma Tumor Diagnostics
-
By Test Type:
- CA 125 Test for Ovarian Cancer Diagnostics
- HER 2 Test for Ovarian Cancer Diagnostics
- BRCA Test for Ovarian Cancer Diagnostics
- CEA Test for Ovarian Cancer Diagnostics
- ER & PR Test for Ovarian Cancer Diagnostics
- KRAS Mutation Test for Ovarian Cancer Diagnostics
- Others
-
By End User:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
Table of Content
- 1. Global Market to Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Cancer Type
- 3.1. Epithelial Tumors
- 3.2. Germ cell carcinoma tumors
- 3.3. Stromal carcinoma tumors
- 4. Global Market Analysis and Forecast By End User
- 4.1. Hospital Associated Labs
- 4.2. Independent Diagnostic Laboratories
- 4.3. Cancer Research Institutes
- 4.4. Others
- 5. Global Market Analysis and Forecast By Test Type
- 5.1. CA 125
- 5.2. HER 2
- 5.3. BRCA
- 5.4. CEA
- 5.5. ER & PR
- 5.6. KRAS Mutation
- 5.7. Others
- 6. Global Market Analysis and Forecast By Region
- 6.1. North America
- 6.2. Latin America
- 6.3. Europe
- 6.4. Japan
- 6.5. APEJ
- 6.6. MEA
- 7. North America Market Analysis and Forecast, By Country, 2016 to 2031
- 8. Latin America Market Analysis and Forecast, By Country, 2016 to 2031
- 9. Europe Market Analysis and Forecast, By Country, 2016 to 2031
- 10. Japan Market Analysis and Forecast, By Country, 2016 to 2031
- 11. APEJ Market Analysis and Forecast, By Country, 2016 to 2031
- 12. MEA Market Analysis and Forecast, By Country, 2016 to 2031
- 13. Company Profiles
- 13.1. Abbott Laboratories
- 13.2. Roche Holding AG
- 13.3. Thermo Fisher Scientific Inc.
- 13.4. Siemens AG
- 13.5. Bio-Rad Laboratories, Inc.
- 13.6. Illumina, Inc.
- 13.7. Epigenomics AG
- 13.8. AstraZeneca plc
- 13.9. Myriad Genetics Inc.
- 13.10. Quest Diagnostics Incorporated
- 14. Disclaimer and Contact Information
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 1 Global Market Value (US$ Mn), 2016 to 2020
TABLE 2 Global Market Value (US$ Mn), 2021 to 2031
TABLE 3 Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2031
TABLE 4 Global Epithelial Tumors Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 5 Global Epithelial Tumors Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 6 Global Epithelial Tumors Segment Market Share, By Region 2016 to 2020
TABLE 7 Global Epithelial Tumors Segment Market Share, By Region 2021 to 2031
TABLE 8 Global Epithelial Tumors Segment Y-o-Y, By Region 2015 to 2031
TABLE 9 Global Germ cell carcinoma tumors Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 10 Global Germ cell carcinoma tumors Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 11 Global Germ cell carcinoma tumors Segment Market Share, By Region 2016 to 2020
TABLE 12 Global Germ cell carcinoma tumors Segment Market Share, By Region 2021 to 2031
TABLE 13 Global Germ cell carcinoma tumors Segment Y-o-Y, By Region 2015 to 2031
TABLE 14 Global Stromal carcinoma tumors Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 15 Global Stromal carcinoma tumors Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 16 Global Stromal carcinoma tumors Segment Market Share, By Region 2016 to 2020
TABLE 17 Global Stromal carcinoma tumors Segment Market Share, By Region 2021 to 2031
TABLE 18 Global Stromal carcinoma tumors Segment Y-o-Y, By Region 2015 to 2031
TABLE 19 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 20 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 21 Global Hospital Associated Labs Segment Market Share, By Region 2016 to 2020
TABLE 22 Global Hospital Associated Labs Segment Market Share, By Region 2021 to 2031
TABLE 23 Global Hospital Associated Labs Segment Y-o-Y, By Region 2015 to 2031
TABLE 24 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 25 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 26 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2016 to 2020
TABLE 27 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2021 to 2031
TABLE 28 Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015 to 2031
TABLE 29 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 30 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 31 Global Cancer Research Institutes Segment Market Share, By Region 2016 to 2020
TABLE 32 Global Cancer Research Institutes Segment Market Share, By Region 2021 to 2031
TABLE 33 Global Cancer Research Institutes Segment Y-o-Y, By Region 2015 to 2031
TABLE 34 Global Others Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 35 Global Others Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 36 Global Others Segment Market Share, By Region 2016 to 2020
TABLE 37 Global Others Segment Market Share, By Region 2021 to 2031
TABLE 38 Global Others Segment Y-o-Y, By Region 2015 to 2031
TABLE 39 Global CA 125 Segment Value (US$ Mn), By Region 2016 to 20201
TABLE 40 Global CA 125 Segment Value (US$ Mn), By Region 2021 to 20311
TABLE 41 Global CA 125 Segment Market Share, By Region 2016 to 2020
TABLE 42 Global CA 125 Segment Market Share, By Region 2021 to 2031
TABLE 43 Global CA 125 Segment Y-o-Y, By Region 2015 to 2031
TABLE 44 Global HER 2 Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 45 Global HER 2 Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 46 Global HER 2 Segment Market Share, By Region 2016 to 2020
TABLE 47 Global HER 2 Segment Market Share, By Region 2021 to 2031
TABLE 48 Global HER 2 Segment Y-o-Y, By Region 2015 to 2031
TABLE 49 Global BRCA Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 50 Global BRCA Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 51 Global BRCA Segment Market Share, By Region 2016 to 2020
TABLE 52 Global BRCA Segment Market Share, By Region 2021 to 2031
TABLE 53 Global BRCA Segment Y-o-Y, By Region 2015 to 2031
TABLE 54 Global CEA Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 55 Global CEA Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 56 Global CEA Segment Market Share, By Region 2016 to 2020
TABLE 57 Global CEA Segment Market Share, By Region 2021 to 2031
TABLE 58 Global CEA Segment Y-o-Y, By Region 2015 to 2031
TABLE 59 Global ER & PR segment Value (US$ Mn), By Region 2016 to 2020
TABLE 60 Global ER & PR segment Value (US$ Mn), By Region 2021 to 2031
TABLE 61 Global ER & PR segment Market Share, By Region 2016 to 2020
TABLE 62 Global ER & PR segment Market Share, By Region 2021 to 2031
TABLE 63 Global ER & PR segment Y-o-Y, By Region 2015 to 2031
TABLE 64 Global KRAS Mutation Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 65 Global KRAS Mutation Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 66 Global KRAS Mutation Segment Market Share, By Region 2016 to 2020
TABLE 67 Global KRAS Mutation Segment Market Share, By Region 2021 to 2031
TABLE 68 Global KRAS Mutation Segment Y-o-Y, By Region 2015 to 2031
TABLE 69 Global Others Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 70 Global Others Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 71 Global Others Segment Market Share, By Region 2016 to 2020
TABLE 72 Global Others Segment Market Share, By Region 2021 to 2031
TABLE 73 Global Others Segment Y-o-Y, By Region 2015 to 2031
TABLE 74 North America Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 75 North America Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 76 North America Market Value (US$ Mn), By End User 2016 to 2020
TABLE 77 North America Market Value (US$ Mn), By End User 2021 to 2031
TABLE 78 North America Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 79 North America Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 80 Latin America Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 81 Latin America Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 82 Latin America Market Value (US$ Mn), By End User 2016 to 2020
TABLE 83 Latin America Market Value (US$ Mn), By End User 2021 to 2031
TABLE 84 Latin America Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 85 Latin America Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 86 Europe Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 87 Europe Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 88 Europe Market Value (US$ Mn), By End User 2016 to 2020
TABLE 89 Europe Market Value (US$ Mn), By End User 2021 to 2031
TABLE 90 Europe Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 91 Europe Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 92 Japan Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 93 Japan Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 94 Japan Market Value (US$ Mn), By End User 2016 to 2020
TABLE 95 Japan Market Value (US$ Mn), By End User 2021 to 2031
TABLE 96 Japan Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 97 Japan Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 98 APEJ Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 99 APEJ Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 100 APEJ Market Value (US$ Mn), By End User 2016 to 2020
TABLE 101 APEJ Market Value (US$ Mn), By End User 2021 to 2031
TABLE 102 APEJ Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 103 APEJ Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 104 MEA Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 105 MEA Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 106 MEA Market Value (US$ Mn), By End User 2016 to 2020
TABLE 107 MEA Market Value (US$ Mn), By End User 2021 to 2031
TABLE 108 MEA Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 109 MEA Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 110 US Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 111 US Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 112 US Market Value (US$ Mn), By End User 2016 to 2020
TABLE 113 US Market Value (US$ Mn), By End User 2021 to 2031
TABLE 114 US Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 115 US Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 116 Canada Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 117 Canada Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 118 Canada Market Value (US$ Mn), By End User 2016 to 2020
TABLE 119 Canada Market Value (US$ Mn), By End User 2021 to 2031
TABLE 120 Canada Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 121 Canada Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 122 Brazil Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 123 Brazil Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 124 Brazil Market Value (US$ Mn), By End User 2016 to 2020
TABLE 125 Brazil Market Value (US$ Mn), By End User 2021 to 2031
TABLE 126 Brazil Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 127 Brazil Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 128 Mexico Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 129 Mexico Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 130 Mexico Market Value (US$ Mn), By End User 2016 to 2020
TABLE 131 Mexico Market Value (US$ Mn), By End User 2021 to 2031
TABLE 132 Mexico Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 133 Mexico Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 134 Argentina Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 135 Argentina Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 136 Argentina Market Value (US$ Mn), By End User 2016 to 2020
TABLE 137 Argentina Market Value (US$ Mn), By End User 2021 to 2031
TABLE 138 Argentina Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 139 Argentina Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 140 Germany Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 141 Germany Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 142 Germany Market Value (US$ Mn), By End User 2016 to 2020
TABLE 143 Germany Market Value (US$ Mn), By End User 2021 to 2031
TABLE 144 Germany Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 145 Germany Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 146 UK Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 147 UK Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 148 UK Market Value (US$ Mn), By End User 2016 to 2020
TABLE 149 UK Market Value (US$ Mn), By End User 2021 to 2031
TABLE 150 UK Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 151 UK Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 152 France Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 153 France Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 154 France Market Value (US$ Mn), By End User 2016 to 2020
TABLE 155 France Market Value (US$ Mn), By End User 2021 to 2031
TABLE 156 France Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 157 France Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 158 Spain Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 159 Spain Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 160 Spain Market Value (US$ Mn), By End User 2016 to 2020
TABLE 161 Spain Market Value (US$ Mn), By End User 2021 to 2031
TABLE 162 Spain Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 163 Spain Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 164 Italy Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 165 Italy Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 166 Italy Market Value (US$ Mn), By End User 2016 to 2020
TABLE 167 Italy Market Value (US$ Mn), By End User 2021 to 2031
TABLE 168 Italy Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 169 Italy Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 170 Nordic Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 171 Nordic Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 172 Nordic Market Value (US$ Mn), By End User 2016 to 2020
TABLE 173 Nordic Market Value (US$ Mn), By End User 2021 to 2031
TABLE 174 Nordic Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 175 Nordic Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 176 Japan Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 177 Japan Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 178 Japan Market Value (US$ Mn), By End User 2016 to 2020
TABLE 179 Japan Market Value (US$ Mn), By End User 2021 to 2031
TABLE 180 Japan Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 181 Japan Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 182 China Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 183 China Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 184 China Market Value (US$ Mn), By End User 2016 to 2020
TABLE 185 China Market Value (US$ Mn), By End User 2021 to 2031
TABLE 186 China Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 187 China Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 188 India Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 189 India Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 190 India Market Value (US$ Mn), By End User 2016 to 2020
TABLE 191 India Market Value (US$ Mn), By End User 2021 to 2031
TABLE 192 India Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 193 India Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 194 Malaysia Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 195 Malaysia Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 196 Malaysia Market Value (US$ Mn), By End User 2016 to 2020
TABLE 197 Malaysia Market Value (US$ Mn), By End User 2021 to 2031
TABLE 198 Malaysia Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 199 Malaysia Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 200 Thailand Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 201 Thailand Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 202 Thailand Market Value (US$ Mn), By End User 2016 to 2020
TABLE 203 Thailand Market Value (US$ Mn), By End User 2021 to 2031
TABLE 204 Thailand Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 205 Thailand Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 206 Singapore Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 207 Singapore Market Value (US$ Mn), By Cancer Type 2021 to 203
TABLE 208 Singapore Market Value (US$ Mn), By End User 2016 to 2020
TABLE 209 Singapore Market Value (US$ Mn), By End User 2021 to 2031
TABLE 210 Singapore Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 211 Singapore Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 212 Australia Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 213 Australia Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 214 Australia Market Value (US$ Mn), By End User 2016 to 2020
TABLE 215 Australia Market Value (US$ Mn), By End User 2021 to 2031
TABLE 216 Australia Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 217 Australia Market Value (US$ Mn), By Test Type 2021 to 2031 148
TABLE 218 GCC Countries Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 219 GCC Countries Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 220 GCC Countries Market Value (US$ Mn), By End User 2016 to 2020
TABLE 221 GCC Countries Market Value (US$ Mn), By End User 2021 to 2031
TABLE 222 GCC Countries Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 223 GCC Countries Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 224 South Africa Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 225 South Africa Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 226 South Africa Market Value (US$ Mn), By End User 2016 to 2020
TABLE 227 South Africa Market Value (US$ Mn), By End User 2021 to 2031
TABLE 228 South Africa Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 229 South Africa Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 230 Nigeria Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 231 Nigeria Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 232 Nigeria Market Value (US$ Mn), By End User 2016 to 2020
TABLE 233 Nigeria Market Value (US$ Mn), By End User 2021 to 2031
TABLE 234 Nigeria Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 235 Nigeria Market Value (US$ Mn), By Test Type 2021 to 2031
TABLE 236 Israel Market Value (US$ Mn), By Cancer Type 2016 to 2020
TABLE 237 Israel Market Value (US$ Mn), By Cancer Type 2021 to 2031
TABLE 238 Israel Market Value (US$ Mn), By End User 2016 to 2020
TABLE 239 Israel Market Value (US$ Mn), By End User 2021 to 2031
TABLE 240 Israel Market Value (US$ Mn), By Test Type 2016 to 2020
TABLE 241 Israel Market Value (US$ Mn), By Test Type 2021 to 2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 1 Global Market Value (US$ Mn), 2016 to 2020
FIG. 2 Global Market Value (US$ Mn) Forecast, 2021 to 2031
FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2031
FIG. 4 Global Epithelial Tumors Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 5 Global Epithelial Tumors Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 6 Global Epithelial Tumors Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 7 Global Germ cell carcinoma tumors Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 8 Global Germ cell carcinoma tumors Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 9 Global Germ cell carcinoma tumors Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 10 Global Stromal carcinoma tumors Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 11 Global Stromal carcinoma tumors Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 12 Global Stromal carcinoma tumors Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 13 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 14 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 15 Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 16 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 17 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 18 Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 19 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 20 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 21 Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 22 Global Others Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 23 Global Others Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 24 Global Others Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 25 Global CA 125 Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 26 Global CA 125 Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 27 Global CA 125 Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 28 Global HER 2 Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 29 Global HER 2 Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 30 Global HER 2 Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 31 Global BRCA Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 32 Global BRCA Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 33 Global BRCA Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 34 Global CEA Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 35 Global CEA Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 36 Global CEA Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 37 Global ER & PR segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 38 Global ER & PR segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 39 Global ER & PR segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 40 Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 41 Global KRAS Mutation Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 42 Global KRAS Mutation Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 43 Global Others Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 44 Global Others Segment Market Value (US$ Mn) By Region, 2021 to 2031
FIG. 45 Global Others Segment Y-o-Y Growth Rate, By Region, 2015 to 2031
FIG. 46 North America Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 47 North America Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 48 North America Market Value (US$ Mn), By End User 2016 to 2020
FIG. 49 North America Market Value (US$ Mn), By End User 2021 to 2031
FIG. 50 North America Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 51 North America Market Value (US$ Mn), By Test Type 2021 to 2031
FIG. 52 Latin America Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 53 Latin America Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 54 Latin America Market Value (US$ Mn), By End User 2016 to 2020
FIG. 55 Latin America Market Value (US$ Mn), By End User 2021 to 2031
FIG. 56 Latin America Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 57 Latin America Market Value (US$ Mn), By Test Type 2021 to 2031
FIG. 58 Europe Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 59 Europe Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 60 Europe Market Value (US$ Mn), By End User 2016 to 2020
FIG. 61 Europe Market Value (US$ Mn), By End User 2021 to 2031
FIG. 62 Europe Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 63 Europe Market Value (US$ Mn), By Test Type 2021 to 2031
FIG. 64 Japan Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 65 Japan Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 66 Japan Market Value (US$ Mn), By End User 2016 to 2020
FIG. 67 Japan Market Value (US$ Mn), By End User 2021 to 2031
FIG. 68 Japan Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 69 Japan Market Value (US$ Mn), By Test Type 2021 to 2031
FIG. 70 APEJ Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 71 APEJ Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 72 APEJ Market Value (US$ Mn), By End User 2016 to 2020
FIG. 73 APEJ Market Value (US$ Mn), By End User 2021 to 2031
FIG. 74 APEJ Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 75 APEJ Market Value (US$ Mn), By Test Type 2021 to 2031
FIG. 76 MEA Market Value (US$ Mn), By Cancer Type 2016 to 2020
FIG. 77 MEA Market Value (US$ Mn), By Cancer Type 2021 to 2031
FIG. 78 MEA Market Value (US$ Mn), By End User 2016 to 2020
FIG. 79 MEA Market Value (US$ Mn), By End User 2021 to 2031
FIG. 80 MEA Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 81 MEA Market Value (US$ Mn), By Test Type 2021 to 2031
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What are the latest trends related to ovarian cancer diagnostics?
Increasing incidence of cancer in the general population and rising healthcare expenditure are major trends prevalent in the marketplace.
What does the research say about demand for ovarian cancer diagnostics in the APAC region?
The research predicts the APAC market to exhibit the highest CAGR over the next ten years.
Who are the key players involved in ovarian cancer diagnostics?
Top players such as Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG Illumina Inc., Bio-Rad Laboratories Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories are profiled in t
What end-use application is expected to see most prominent demand?
Use of ovarian cancer diagnostics at independent diagnostic centers is anticipated to experience high demand growth.
What is the estimated CAGR for the global ovarian cancer diagnostics industry over the decade?
Demand for ovarian cancer diagnostics is predicted to surge at a CAGR of approximately 7% through 2031.
What was the net worth of ovarian cancer diagnostic marketplace in 2020?
The global ovarian cancer diagnostics market amassed a net worth of approximately US$ 1.3 Bn in the year 2020.
Which ovarian cancer type diagnostics accounts for majority market share?
Epithelial tumor diagnostics holds a dominant market share in the market as per cancer type.
What is a major challenge for ovarian cancer diagnostic providers?
Early detection is a major challenge for ovarian cancer diagnostic methods.
Ovarian Cancer Diagnostics Market